Rajendra D Badgaiyan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/280569/publications.pdf

Version: 2024-02-01

		331670	315739
82	1,778	21	38
papers	citations	h-index	g-index

84	84	84	856
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Molecular role of dopamine in anhedonia linked to reward deficiency syndrome RDS and anti- reward systems. Frontiers in Bioscience - Scholar, 2018, 10, 309-325.	2.1	111
2	Enhanced functional connectivity and volume between cognitive and reward centers of naÃ¯ve rodent brain produced by pro-dopaminergic agent KB220Z. PLoS ONE, 2017, 12, e0174774.	2.5	92
3	Genetic addiction risk score GARS trade a predictor of vulnerability to opioid dependence. Frontiers in Bioscience - Elite, 2018, 10, 175-196.	1.8	92
4	Dopamine homeostasis brain functional connectivity in reward deficiency syndrome. Frontiers in Bioscience - Landmark, 2017, 22, 669-691.	3.0	88
5	Attenuated Tonic and Enhanced Phasic Release of Dopamine in Attention Deficit Hyperactivity Disorder. PLoS ONE, 2015, 10, e0137326.	2.5	71
6	Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis. Biomedical Journal of Scientific & Technical Research, 2018, 2, 1-4.	0.1	70
7	A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone. Substance Use and Misuse, 2018, 53, 220-229.	1.4	66
8	Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With â€œDopamine Homeostasisâ€•in Reward Deficiency Syndrome (RDS). Substance Use and Misuse, 2017, 52, 535-547.	1.4	62
9	Co-occurrences of substance use and other potentially addictive behaviors: Epidemiological results from the Psychological and Genetic Factors of the Addictive Behaviors (PGA) Study. Journal of Behavioral Addictions, 2020, 9, 272-288.	3.7	56
10	Hypothesizing that, A Pro-Dopamine Regulator (KB220Z) Should Optimize, but Not Hyper-Activate the Activity of Trace Amine-Associated Receptor 1 (TAAR-1) and Induce Anti-Craving of Psychostimulants in the Long-Term. , 2016, 2, 14-21.		56
11	Coupling Genetic Addiction Risk Score (GARS) and Pro Dopamine Regulation (KB220) to Combat Substance Use Disorder (SUD). Global Journal of Addiction & Rehabilitation Medicine, 2017, 1, .	0.1	56
12	Dopamine is released in the striatum during human emotional processing. NeuroReport, 2010, 21, 1172-1176.	1.2	54
13	Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors. Frontiers in Psychiatry, 2018, 9, 548.	2.6	53
14	Conceptualizing Addiction From an Osteopathic Perspective: Dopamine Homeostasis. Journal of Osteopathic Medicine, 2018, 118, 115-118.	0.8	52
15	Neurogenetic and Epigenetic Correlates of Adolescent Predisposition to and Risk for Addictive Behaviors as a Function of Prefrontal Cortex Dysregulation. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 286-292.	1.3	49
16	The effects of residential dual diagnosis treatment on alcohol abuse. Journal of Systems and Integrative Neuroscience, 2017, 3, .	0.6	47
17	Hypodopaminergia and â€œPrecision Behavioral Managementâ€•(PBM): It is a Generational Family Affair. Current Pharmaceutical Biotechnology, 2020, 21, 528-541.	1.6	42
18	The Food and Drug Addiction Epidemic: Targeting Dopamine Homeostasis. Current Pharmaceutical Design, 2018, 23, 6050-6061.	1.9	40

#	Article	IF	Citations
19	Evidence of Dopaminergic Processing of Executive Inhibition. PLoS ONE, 2011, 6, e28075.	2.5	39
20	KB220Zâ„¢ a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams. Can We Infer Neuroplasticity-induced Changes in the Reward Circuit?. , 2016, 2, 3-13.		29
21	Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy: Fighting Iatrogenic Opioid Dependence. Journal of Addiction Research & Therapy, 2013, 04, 1000163.	0.2	26
22	Detection of dopamine neurotransmission in â€œreal timeâ€• Frontiers in Neuroscience, 2013, 7, 125.	2.8	23
23	A Shared Molecular and Genetic Basis for Food and Drug Addiction. Psychiatric Clinics of North America, 2015, 38, 419-462.	1.3	23
24	Hypothesizing Music Intervention Enhances Brain Functional Connectivity Involving Dopaminergic Recruitment: Common Neuro-correlates to Abusable Drugs. Molecular Neurobiology, 2017, 54, 3753-3758.	4.0	22
25	In Search of Reward Deficiency Syndrome (RDS)-Free Controls: The â€œHoly Grailâ€•in Genetic Addiction Risk Testing. Current Psychopharmacology, 2020, 9, 7-21.	0.3	18
26	Our evolved unique pleasure circuit makes humans different from apes: Reconsideration of data derived from animal studies. Journal of Systems and Integrative Neuroscience, 2018, 4, .	0.6	17
27	Coupling Neurogenetics (GARSâ„¢) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms. Journal of Reward Deficiency Syndrome, 2015, 1, 75-80.	1.0	17
28	Putative COVID- 19 Induction of Reward Deficiency Syndrome (RDS) and Associated Behavioral Addictions with Potential Concomitant Dopamine Depletion: Is COVID-19 Social Distancing a Double Edged Sword?. Substance Use and Misuse, 2020, 55, 2438-2442.	1.4	16
29	Death by Opioids: Are there non-addictive scientific solutions?. Journal of Systems and Integrative Neuroscience, 2019, 5, .	0.6	16
30	Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction. Journal of Reward Deficiency Syndrome, 2015, 01, 65-68.	1.0	16
31	Pro-dopamine regulator, KB220Z, attenuates hoarding and shopping behavior in a female, diagnosed with SUD and ADHD. Journal of Behavioral Addictions, 2018, 7, 192-203.	3.7	15
32	A Novel Precision Approach to Overcome the â€œAddiction Pandemicâ€•by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration. Journal of Personalized Medicine, 2021, 11, 212.	2.5	15
33	Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It â€œBlowinâ€™ in the Windâ€?. Journal of Personalized Medicine, 2022, 12, 321.	2.5	15
34	Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior. Medical Hypotheses, 2014, 82, 606-614.	1.5	14
35	â€œDopamine homeostasisâ€•requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat Americaâ€™s drug epidemic. Journal of Systems and Integrative Neuroscience, 2017, 3, .	0.6	14
36	Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment?. Substance Use and Misuse, 2016, 51, 1674-1679.	1.4	13

#	Article	IF	Citations
37	Exploration of Epigenetic State Hyperdopaminergia (Surfeit) and Genetic Trait Hypodopaminergia (Deficit) during Adolescent Brain Development. Current Psychopharmacology, 2021, 10, 181-196.	0.3	13
38	Nonconscious perception, conscious awareness and attention. Consciousness and Cognition, 2012, 21, 584-586.	1.5	12
39	Pilot clinical observations between food and drug seeking derived from fifty cases attending an eating disorder clinic. Journal of Behavioral Addictions, 2016, 5, 533-541.	3.7	12
40	Neurogenetics of acute and chronic opiate opioid abstinence treating symptoms and the cause. Frontiers in Bioscience - Landmark, 2017, 22, 1247-1288.	3.0	12
41	Pro-Dopamine Regulator - (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS). , 2017, 03, .		12
42	Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions. International Journal of Environmental Research and Public Health, 2021, 18, 11529.	2.6	12
43	Hypothesizing Balancing Endorphinergic and Glutaminergic Systems to Treat and Prevent Relapse to Reward Deficiency Behaviors: Coupling D-Phenylalanine and N-Acetyl-L-Cysteine (NAC) as a Novel Therapeutic Modality. Clinical Medical Reviews and Case Reports, 2015, 2, .	0.1	11
44	Low-Resolution Electromagnetic Tomography (LORETA) of changed Brain Function Provoked by Pro-Dopamine Regulator (KB220z) in one Adult ADHD case. Open Journal of Clinical & Medical Case Reports, 2016, 2, .	1.0	11
45	GLOBAL OPIOID EPIDEMIC: DOOMED TO FAIL WITHOUT GENETICALLY BASED PRECISION ADDICTION MEDICINE (PAM): LESSONS LEARNED FROM AMERICA. Precision Medicine, 2017, 2, 17-22.	3.5	11
46	Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual. Journal of Systems and Integrative Neuroscience, 2020, 6, .	0.6	10
47	Genetic Addiction Risk Score (GARS) as a Predictor of Substance Use Disorder: Identifying Predisposition Not Diagnosis. , 2018, 1, .		10
48	Diet and companionship modulate pain via a serotonergic mechanism. Scientific Reports, 2021, 11, 2330.	3.3	9
49	Lyme and dopaminergic function: Hypothesizing reduced reward deficiency symptomatology by regulating dopamine transmission. Journal of Systems and Integrative Neuroscience, 2017, 3, .	0.6	8
50	A Novel Perspective on Dopaminergic Processing of Human Addiction. Journal of Alcoholism and Drug Dependence, 2013, 01, .	0.2	8
51	Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency. Journal of Addiction Science, 2020, 06, .	0.5	7
52	Neurobiology of KB220Z-Glutaminergic-Dopaminergic Optimization Complex [GDOC] as a Liquid Nano: Clinical Activation of Brain in a Highly Functional Clinician Improving Focus, Motivation and Overall Sensory Input Following Chronic Intake. Clinical Medical Reviews and Case Reports, 2016, 3, .	0.1	7
53	Pro-Dopamine Regulator - (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS). , 2017, 3, 3-13.		7
54	Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse. , 2018, 7, 564-579.		7

#	Article	IF	Citations
55	In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk Testing. Current Psychopharmacology, 2020, 9, 7-21.	0.3	7
56	Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors. International Journal of Environmental Research and Public Health, 2022, 19, 552.	2.6	7
57	A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing â€œPrecision Behavioral Managementâ€. Psychology Research and Behavior Management, 2021, Volume 14, 2115-2134.	2.8	7
58	Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility. Addiction Genetics, 2015, 2, 1-5.	0.5	6
59	Improvement of long-term memory access with a pro-dopamine regulator in an elderly male: Are we targeting dopamine tone?. Journal of Systems and Integrative Neuroscience, 2017, 3, .	0.6	6
60	Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence?. International Journal of Environmental Research and Public Health, 2022, 19, 6395.	2.6	6
61	Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine Regulation. Journal of Personalized Medicine, 2022, 12, 1009.	2.5	6
62	Epigenetic Repair of Terrifying Lucid Dreams by Enhanced Brain Reward Functional Connectivity and Induction of Dopaminergic Homeo - static Signaling. Current Psychopharmacology, 2021, 10, 170-180.	0.3	5
63	Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?. International Journal of Environmental Research and Public Health, 2021, 18, 9774.	2.6	5
64	Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics.. Cureus, 2015, 7, e290.	0.5	5
65	Hypothesizing High Negative Emotionality as a Function of Genetic Addiction Risk Severity (GARS) Testing in Alcohol Use Disorder (AUD). Journal of Systems and Integrative Neuroscience, 2020, 7, .	0.6	5
66	Endorphinergic Enhancement Attenuation of Post-traumatic Stress Disorder (PTSD) via Activation of Neuro-immunological Function in the Face of a Viral Pandemic. Current Psychopharmacology, 2021, 10, 86-97.	0.3	4
67	Can Genetic Testing Provide Information to Develop Customized Nutrigenomic Solutions for Reward Deficiency Syndrome?. Clinical Medical Reviews and Case Reports, 2015, 2, .	0.1	4
68	Physical Exercise Interventions for Drug Addictive Disorders. , 2017, 3, 17-20.		3
69	Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise. Current Psychopharmacology, 2021, 10, 123-137.	0.3	2
70	Activation of the Central Serotonergic System Reduces Hyperalgesia in Sickle Mice. Blood, 2016, 128, 266-266.	1.4	2
71	Nonconscious processing and a novel target for schizophrenia research. Open Journal of Psychiatry, 2012, 02, 335-339.	0.6	2
72	Polygenic and multi locus heritability of alcoholism: Novel therapeutic targets to overcome psychological deficits. Journal of Systems and Integrative Neuroscience, 2020, 7, .	0.6	2

#	Article	IF	Citations
73	Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency. , 2020, 6, 1-4.		2
74	Should We Embrace the Incorporation of Genetically Guided "Dopamine Homeostasis" in the Treatment of Reward Deficiency Syndrome (RSD) as a Frontline Therapeutic Modality?. Acta Scientific Neurology, 2021, 4, 17-24.	0.1	2
75	Manipulation of the extrastriate frontal loop can resolve visual disability in blindsight patients. Medical Hypotheses, 2012, 79, 767-769.	1.5	1
76	Attenuation of Regional Cerebral Blood Flow During Memory Processing After Coronary Artery Bypass Surgery. Anesthesia and Analgesia, 2014, 119, 550-553.	2.2	1
77	Addiction Research and Therapy in the 21st Century: Providing a Forum for Evidence -Based Addiction Medicine. Journal of Addiction Research & Therapy, 2013, 04, .	0.2	1
78	Neurobiology and Spirituality in Addiction Recovery.. Acta Scientific Neurology, 2021, 4, 64-71.	0.1	1
79	Buprenorphine and Naloxone Combinations and Dopamine. Current Psychopharmacology, 2018, 6, .	0.3	0
80	Psychoactive Drugs Like Cannabis -Induce Hypodopaminergic Anhedonia and Neuropsychological Dysfunction in Humans: Putative Induction of Dopamine Homeostasis via Coupling of Genetic Addiction Risk Severity (GARS) testing and Precision Pro-dopamine Regulation (KB220). , 2021, 13, 86-92.		0
81	Translational and Molecular Cytoarchitectural Genetic Guided Therapy to Induce Dopamine Homeostatic Neuro-signaling in Reward Deficiency and Associated Drug and Behavioral Addiction Seeking: A 60 Year Sojourn the Future is Now. , 2021, 10, 1-4.		0
82	Nicotinamide adenine dinucleotide (NAD+) and Enkephalinase Inhibition (IV1114589NAD) infusions significantly attenuates psychiatric burden sequalae in Substance Use Disorder (SUD) in fifty cases. Current Psychiatry Research and Reviews, 2022, 18, .	0.2	0